Outlook Therapeutics, Inc. (OTLK) Latest Company News

Aug 27, 2026, 00:00 UTC
Lawrence A. Kenyon departed as Chief Financial Officer, Treasurer and Corporate Secretary of Outlook Therapeutics, Inc. effective September 1, 2026, and Kevin Lundquist was appointed as his successor, effective the same date.
Aug 14, 2026, 00:00 UTC
Outlook Therapeutics reported Q3 FY2026 net revenue of $9 thousand, down from $1.505 million in Q3 FY2025, with a GAAP net loss of $20.3 million ($0.15 per diluted share) and a non-GAAP adjusted net loss of $10.9 million ($0.09 per diluted share).
Source:
- zacks.com
Aug 12, 2026, 20:01 UTC
Outlook Therapeutics announced the commencement of an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock, with a 30-day option for underwriters to purchase up to 15% additional shares and/or warrants.
Source:
Aug 10, 2026, 16:31 UTC
Outlook Therapeutics plans to launch Lytenava in the U.S. by the end of 2026, following FDA approval.
Source:
Jul 24, 2026, 19:00 UTC
The U.S. Food and Drug Administration approved Outlook Therapeutics' drug for a type of eye disease that can cause severe vision loss.
Source:
Jun 16, 2026, 12:02 UTC
The FDA accepted Outlook Therapeutics' resubmitted Biologics License Application for ONS-5010/LYTENAVA as a treatment for wet AMD.
Source:
Jun 1, 2026, 12:46 UTC
Outlook Therapeutics resubmitted its Biologics License Application to the U.S. FDA for ONS-5010/LYTENAVA for treating neovascular age-related macular degeneration.
Source:
- globenewswire.com

OTLK

Lawrence A. Kenyon departed as Chief Financial Officer, Treasurer and Corporate Secretary of Outlook Therapeutics, Inc. effective September 1, 2026, and Kevin Lundquist was appointed as his successor, effective the same date.

Outlook Therapeutics reported Q3 FY2026 net revenue of $9 thousand, down from $1.505 million in Q3 FY2025, with a GAAP net loss of $20.3 million ($0.15 per diluted share) and a non-GAAP adjusted net loss of $10.9 million ($0.09 per diluted share).

Outlook Therapeutics announced the commencement of an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock, with a 30-day option for underwriters to purchase up to 15% additional shares and/or warrants.

Outlook Therapeutics plans to launch Lytenava in the U.S. by the end of 2026, following FDA approval.

The U.S. Food and Drug Administration approved Outlook Therapeutics' drug for a type of eye disease that can cause severe vision loss.

The FDA accepted Outlook Therapeutics' resubmitted Biologics License Application for ONS-5010/LYTENAVA as a treatment for wet AMD.

Outlook Therapeutics resubmitted its Biologics License Application to the U.S. FDA for ONS-5010/LYTENAVA for treating neovascular age-related macular degeneration.